AU2015346205B2 - Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof - Google Patents

Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Download PDF

Info

Publication number
AU2015346205B2
AU2015346205B2 AU2015346205A AU2015346205A AU2015346205B2 AU 2015346205 B2 AU2015346205 B2 AU 2015346205B2 AU 2015346205 A AU2015346205 A AU 2015346205A AU 2015346205 A AU2015346205 A AU 2015346205A AU 2015346205 B2 AU2015346205 B2 AU 2015346205B2
Authority
AU
Australia
Prior art keywords
antibody
humanized
binding
cspg4
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2015346205A
Other languages
English (en)
Other versions
AU2015346205A1 (en
Inventor
Ming Cheng
Nai-Kong V. Cheung
Soldano Ferrone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Original Assignee
General Hospital Corp
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp, Memorial Sloan Kettering Cancer Center filed Critical General Hospital Corp
Publication of AU2015346205A1 publication Critical patent/AU2015346205A1/en
Application granted granted Critical
Publication of AU2015346205B2 publication Critical patent/AU2015346205B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2015346205A 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof Ceased AU2015346205B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462078849P 2014-11-12 2014-11-12
US62/078,849 2014-11-12
PCT/US2015/060465 WO2016077638A1 (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
AU2015346205A1 AU2015346205A1 (en) 2017-06-01
AU2015346205B2 true AU2015346205B2 (en) 2021-07-29

Family

ID=55955081

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015346205A Ceased AU2015346205B2 (en) 2014-11-12 2015-11-12 Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof

Country Status (6)

Country Link
US (1) US11091547B2 (Direct)
EP (1) EP3218413A4 (Direct)
JP (1) JP6779873B2 (Direct)
AU (1) AU2015346205B2 (Direct)
CA (1) CA2967350C (Direct)
WO (1) WO2016077638A1 (Direct)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
AU2019287676A1 (en) 2018-06-13 2021-01-07 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells
KR20210080460A (ko) 2018-10-23 2021-06-30 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체성 Fc-융합된 단백질
JOP20210298A1 (ar) 2019-05-14 2023-01-30 Provention Bio Inc طرق وتركيبات للوقاية من مرض السكري من النوع الأول
KR20230004746A (ko) 2020-04-22 2023-01-06 드래곤플라이 쎄라퓨틱스, 인크. 이종이량체 fc-융합 단백질에 대한 제형, 투여 요법 및 제조 방법
CN111575241B (zh) * 2020-05-29 2022-09-13 复旦大学附属眼耳鼻喉科医院 一种嵌合硫酸软骨素蛋白多糖4受体的t淋巴细胞及其制备方法和用途
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN115867584A (zh) * 2020-06-29 2023-03-28 细胞医学公司 用于减少嵌合抗原受体强直信号传导的方法和组合物
CN114249832B (zh) * 2020-09-24 2023-11-10 博源润生医药（杭州）有限公司 一种靶向cpsg4的人源化嵌合抗原受体及表达该嵌合抗原受体的免疫效应细胞及其应用
WO2022133169A1 (en) 2020-12-18 2022-06-23 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
IL308809A (en) * 2021-06-04 2024-01-01 Amgen Res Munich Gmbh T cell binding compounds and their uses
JP2024546096A (ja) * 2021-12-07 2024-12-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ コンドロイチン硫酸プロテオグリカン（ｃｓｐｇ４）ポリペプチドの結合剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009090A1 (en) * 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
WO2013092001A1 (en) * 2011-12-19 2013-06-27 Synimmune Gmbh Bispecific antibody molecule

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
EP2142569A2 (en) * 2007-03-28 2010-01-13 Biogen Idec, Inc. Non-fucosylated antibodies
EP2338055A4 (en) * 2008-09-19 2012-10-31 Univ Pittsburgh MONOCLONAL ANTIBODIES FOR CSPG4 FOR THE DIAGNOSIS AND TREATMENT OF BASAL MAMMARY CARCINOMA
EP2334701A4 (en) * 2008-10-16 2014-01-08 Univ Pittsburgh FULLY HUMAN ANTIBODIES AGAINST ANTIGENES ASSOCIATED WITH MELANOMA OF HIGH MOLECULAR WEIGHT AND USES THEREOF
DK2483310T3 (da) 2009-09-29 2014-09-01 Roche Glycart Ag Bispecifik dødsreceptor-agonistiske antistoffer
US9315585B2 (en) * 2010-06-19 2016-04-19 Memorial Sloan Kettering Cancer Center Anti-GD2 antibodies
US9296811B2 (en) * 2010-12-02 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds HMW-MAA
WO2013102123A2 (en) * 2011-12-28 2013-07-04 Novelmed Therapeutics, Inc. Aglycosylated human antibody and fusion protein and uses thereof
SMT202200295T1 (it) * 2012-05-18 2022-09-14 Aptevo Res & Development Llc Immunofusione bispecifica (bif) di scfv legante cd123 e cd3
NZ708182A (en) 2013-02-26 2019-08-30 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
AU2014225788B2 (en) * 2013-03-05 2018-03-29 Baylor College Of Medicine Engager cells for immunotherapy
WO2014165644A2 (en) * 2013-04-04 2014-10-09 The General Hospital Corporation Combination treatments with sonic hedgehog inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011009090A1 (en) * 2009-07-16 2011-01-20 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
WO2013092001A1 (en) * 2011-12-19 2013-06-27 Synimmune Gmbh Bispecific antibody molecule

Also Published As

Publication number Publication date
EP3218413A4 (en) 2018-03-28
EP3218413A1 (en) 2017-09-20
US11091547B2 (en) 2021-08-17
JP6779873B2 (ja) 2020-11-04
WO2016077638A1 (en) 2016-05-19
JP2017537082A (ja) 2017-12-14
CA2967350A1 (en) 2016-05-19
CA2967350C (en) 2021-11-23
US20170342151A1 (en) 2017-11-30
AU2015346205A1 (en) 2017-06-01

Similar Documents

Publication Publication Date Title
AU2015346205B2 (en) Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
US11981742B2 (en) Antibody agents specific for human CD19 and uses thereof
US11673957B2 (en) Anti-ROR2 antibodies
EP3105252B1 (en) Bispecific antibodies for use in stem cell transplantation
KR102089114B1 (ko) 항원 결합 단백질 및 암의 치료를 위한 어드레싱 산물로서 그의 용도
CA2902561C (en) Multimerization technologies
JP7403479B2 (ja) Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
US20240150464A1 (en) Materials and methods for modulating t cell mediated immunity
CN110325209A (zh) 能够结合cd137和肿瘤抗原的双特异性结合分子及其用途
CN108495864A (zh) 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
CN112566937A (zh) 对cd3特异性的抗体及其用途
RU2773317C2 (ru) Антительные агенты, специфичные к cd19 человека, и их применения
HK40071400A (en) Antibody agents specific for human cd19 and uses thereof
HK40071400B (zh) 对人类cd19具有专一性的抗体药剂和其用途
HK40046552A (en) Antibodies specific for cd3 and uses thereof
HK1241907A1 (en) Antibody agents specific for human cd19 and uses thereof
HK1241907B (zh) 对人类cd19具有专一性的抗体药剂和其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired